Clincosm LogoSign in Get a demo

Carcinoma, Hepatocellular

Showing 26 - 50 of 259
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Carcinoma, Hepatocellular Trial in Germany, United States (Regorafenib(Stivarga, BAY73-4506), Pembrolizumab)

Active, not recruiting
  • Carcinoma, Hepatocellular
  • Los Angeles, California
  • +6 more
Aug 15, 2022

Tolerability of Lenvatinib in Advanced or Unresectable

Recruiting
  • Carcinoma, Hepatocellular
  • Clovis, California
  • +48 more
Aug 12, 2022

Carcinoma, Hepatocellular, Cirrhosis Trial in Seattle (Abbreviated Magnetic Resonance Imaging with serum AFP, Abdominal

Not yet recruiting
  • Carcinoma, Hepatocellular
  • Cirrhosis
  • Abbreviated Magnetic Resonance Imaging with serum AFP
  • Abdominal Ultrasound Screening with serum AFP
  • Seattle, Washington
    VA Puget Sound Health Care System Seattle Division, Seattle, WA
Aug 1, 2022

Carcinoma, Hepatocellular, Colorectal Tumors, Pancreatic Ductal Adenocarcinoma Trial in Worldwide (Pembrolizumab, Belzutifan,

Recruiting
  • Carcinoma, Hepatocellular
  • +5 more
  • Duarte, California
  • +39 more
Jul 29, 2022

Carcinoma, Hepatocellular, Gastric/Gastroesophageal Junction Cancer Trial in China (Sitravatinib, Sitravatinib plus

Active, not recruiting
  • Carcinoma, Hepatocellular
  • Gastric/Gastroesophageal Junction Cancer
  • Hefei, Anhui, China
  • +17 more
Jul 28, 2022

Carcinoma, Hepatocellular Trial in United States (Everolimus, Tacrolimus, Myfortic)

Active, not recruiting
  • Carcinoma, Hepatocellular
  • San Francisco, California
  • +8 more
Jul 19, 2022

Carcinoma, Hepatocellular Trial in Worldwide (Atezolizumab, Bevacizumab, Sorafenib)

Active, not recruiting
Has Results
  • Carcinoma, Hepatocellular
  • Phoenix, Arizona
  • +118 more
Jun 14, 2022

Carcinoma, Hepatocellular Trial in Taiwan (PI-88)

Completed
Has Results
  • Carcinoma, Hepatocellular
  • Kaohsiung, Taiwan
  • +5 more
Jun 21, 2022

Carcinoma, Hepatocellular Trial in Shanghai (Pembrolizumab+Lenvatinib)

Not yet recruiting
  • Carcinoma, Hepatocellular
  • Shanghai, Shanghai, China
    Zhongshan hospital
May 24, 2022

Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Advanced

Not yet recruiting
  • Carcinoma, Hepatocellular
    • (no location specified)
    May 16, 2022

    Possible Differences in HCC Course Depending on DAA Treatment

    Recruiting
    • Carcinoma, Hepatocellular
    • +5 more
    • Direct Acting Antivirals
    • Warsaw, Mazowieckie, Poland
      Medical University of Warsaw
    May 11, 2022

    Carcinoma, Hepatocellular, Body Weight Trial in Seoul (low dose CT contrast media - lean body weight, Standard dose CT contrast

    Completed
    • Carcinoma, Hepatocellular
    • Body Weight
    • low dose CT contrast media - lean body weight
    • Standard dose CT contrast media
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    Apr 27, 2022

    Tumor Micronecrosis on Postoperative Transcatheter Arterial

    Completed
    • Carcinoma, Hepatocellular
    • transcatheter arterial chemoembolization
    • Hangzhou, Zhejiang, China
      the First Affiliated Hospital, Zhejiang University School of Med
    Apr 22, 2022

    Carcinoma, Hepatocellular Trial in Navi Mumbai (radiation, procedure, drug)

    Recruiting
    • Carcinoma, Hepatocellular
    • SBRT
    • +2 more
    • Navi Mumbai, Maharashtra, India
    • +1 more
    Apr 25, 2022

    Acquisition Time, Respiratory Gating and New Qclear

    Completed
    • Carcinoma, Hepatocellular
    • PET/CT Exam
    • Bordeaux, France
      CHU Bordeaux
    Mar 29, 2022

    BioTraceIO Lite for Tissue Damage Assessment Following Liver

    Recruiting
    • Carcinoma, Hepatocellular
    • Metastatic Liver Cancer
    • BioTraceIO Lite
    • Phoenix, Arizona
    • +5 more
    Mar 23, 2022

    Glycotest™ HCC Panel vs AFP for Detection of Early-stage

    Recruiting
    • Carcinoma, Hepatocellular
    • Cirrhosis, Liver
      • Los Angeles, California
      • +19 more
      Mar 14, 2022

      Carcinoma, Hepatocellular Trial in Hong Kong (embolization)

      Recruiting
      • Carcinoma, Hepatocellular
      • embolization
      • Hong Kong, Hong Kong
        Department of Imaging and Interventional Radiology, Prince of Wa
      Mar 10, 2022

      Carcinoma, Hepatocellular Trial in Hong Kong (Ablative chemoembolization (ACE))

      Recruiting
      • Carcinoma, Hepatocellular
      • Ablative chemoembolization (ACE)
      • Hong Kong, Hong Kong
        Department of Imaging and Interventional Radiology, Prince of Wa
      Mar 10, 2022

      Overall Survival in Unresectable Hepatocellular Carcinoma

      Completed
      • Carcinoma, Hepatocellular
      • +3 more
      • Osaka, Japan
      • +1 more
      Mar 7, 2022

      Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular

      Active, not recruiting
      • Hepatitis B
      • +2 more
        • Rochester, Minnesota
          Mayo Clinic
        Mar 4, 2022

        Carcinoma, Hepatocellular Trial in Worldwide (biological, drug, other)

        Active, not recruiting
        • Carcinoma, Hepatocellular
        • pembrolizumab
        • +2 more
        • Hefei, Anhui, China
        • +40 more
        Mar 3, 2022

        HER2-positive, Adenocarcinoma, Bile Duct Cancer Trial in United States (CT-0508)

        Recruiting
        • HER2-positive
        • +30 more
        • CT-0508
        • Duarte, California
        • +4 more
        Feb 1, 2022

        Carcinoma, Hepatocellular, Liver Tumors, Tumors, Glandular and Epithelial Trial in Nanning (Hepatic Resection, Radiofrequency

        Recruiting
        • Carcinoma, Hepatocellular
        • +2 more
        • Hepatic Resection
        • Radiofrequency Ablation
        • Nanning, Guangxi, China
          Department of Hepatobilliary Surgery, Affiliated Tumor of Guangx
        Jan 14, 2022

        Carcinoma, Hepatocellular Trial in France (Idarubicin and Lipiodol)

        Recruiting
        • Carcinoma, Hepatocellular
        • Idarubicin and Lipiodol
        • Angers, France
        • +3 more
        Dec 24, 2021